title: Targeted therapies in gynecologic cancers and melanoma.
abstract: The article reviews the main molecular pathology alterations of endometrial and ovarian carcinomas and melanoma. Several promising drugs targeting the genes most frequently altered in these tumors are under consideration. The most promising signaling pathways to be targeted for therapies in these tumors are the tyrosine kinase receptor (EGFR, HER2, c-KIT), the RAS/B-RAF/MAPK, the PI3K-mTOR, and apoptosis signaling pathways.
authors.affiliation: Department of Medical Oncology, Dermatology, and Pathology, Hospital Universitari Arnau de Vilanova, University of Lleida-IRB Lleida, Lleida, Spain.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Ortega
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Marti
authors.forename: Andree
authors.initials: A
authors.lastname: Yeramian
authors.forename: Anabel
authors.initials: A
authors.lastname: Sorolla
authors.forename: Xavier
authors.initials: X
authors.lastname: Dolcet
authors.forename: David
authors.initials: D
authors.lastname: Llobet
authors.forename: Leandro
authors.initials: L
authors.lastname: Abal
authors.forename: Maria
authors.initials: M
authors.lastname: Santacana
authors.forename: Judit
authors.initials: J
authors.lastname: Pallares
authors.forename: Antonio
authors.initials: A
authors.lastname: Llombart-Cussac
authors.forename: Xavier
authors.initials: X
authors.lastname: Matias-Guiu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents